Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV-NIS in Recurrent Medulloblastoma or ATRT
NCT02962167Phase 1Completed
- Start
- Feb 2017
- Primary completion
- May 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of MV-NIS in medulloblastoma and Atypical teratoid rhabdoid tumor (ATRT) (3 arms). Primary endpoints: Number of Participants with Adverse Events as Assessed by CTCAE v5 at 12 months and Recommended Phase 2 Dose at 12 months. Started Feb 2017; status: completed.
02
Drugs
MV-NIS
03
Conditions
medulloblastomaAtypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on NCT02962167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02962167.